Lyme Cysts and Biofilms
Biofilms have been recently discovered as one of the key biological roadblocks to curing many chronic diseases - including MRSA, Herpes and Lyme disease. It is a remarkable breakthrough, and it ultimately could have a huge effect on Lyme disease sufferers and a longer life expectancy among those infected.
Bacteria, including Lyme disease, build biofilms by first rapidly weaving a protective web or matrix around them. They’re very crafty in creating a way to survive and procreate and hide from the immune system. The layer of fibrin covering these microbes allows them to hide and make them undetectable by antibiotics and the immune system.
However, if we can dissolve the fibrin biofilms, our Ultimate Monolaurin and the immune system can more easily identify and eliminate Lyme disease.
The Serrapeptase Alternative
Serrapeptase is a relatively new ‘rising star’ enzyme on its way to becoming the biggest enzyme of all time. It was discovered in the early 70’s and is now in wide clinical use throughout Europe and Asia as an anti-inflammatory and fibrin dissolver for 35 years.
Serrapeptase was originally found in the silkworm where it is a part of the silkworm’s body chemistry. The silkworm has a special relationship with microorganisms. The enzymes secreted by the bacteria in silkworm intestines have the ability to dissolve the cocoon tissue. The silkworm uses this enzyme to dissolve its protective cocoon, so the winged creature is able to emerge and fly away. Obviously, if it can dissolve a cocoon, we have an interest in it dissolving Lyme cysts and biofilm.(1)
Sure enough, this enzyme has been found to be very effective at dissolving non-living tissue, especially internal scar tissue, lesions, mucus and inflammation associated with pain – and our favorite: fibrin bio-coatings! Yes, serrapeptase dissolves blood clots, cysts, and arterial plaque and inflammation in all forms. The uses are wide ranging and cover just about every condition that is affected by inflammation and/or non-living tissue.
For 25 years, Serrapeptase has been studied and is used worldwide to treat numerous medical conditions including arthritis, asthma, bronchitis, cardiovascular disease, to name a few. It has been used successfully in China’s four top hospitals in nerve and infectious diseases since 1995 without any harmful side effects.
Dissolves the biofilms coating microbes like Lyme and for autism.
Allowing the colonies hiding behind biofilms to be destroyed.
Dissolves the fibrin (a kind of plaster) walls of capillaries.
Even dissolves plaque in arteries.
Helps clear mucus from the lungs.
One of the significant advantages of Serrapeptase is that it does not affect the cells or tissues in the human body in good condition. As we said, it dissolves only non-living tissues such as cysts and biofilms.(2)
Hans Nieper is a German doctor known for his treatment of atherosclerosis. He named serrapeptase a "miracle enzyme" after using ultrasound to measure its ability to dissolve arterial plaque without affecting cells! Serrapeptase is a proteolytic enzyme that offers safe but powerful anti-inflammatory properties and fibrin busting ability.
Serrapeptase is also an excellent alternative to aspirin (salicylates), Ibuprofen and the more potent NSAIDs drugs - without all their nasty side effects! Unlike these drugs, serrapeptase is a naturally occurring enzyme with no hindering effects on prostaglandins and no gastrointestinal side effects.
A study in Italy disclosed 91% of those taking serrapeptase reported good to excellent results compared to 22% in the control subjects.(3) Knee cartilage operations were followed by 50% less swelling in the group of patients taking serrapeptase.(4) Twenty patients with carpal tunnel syndrome were given 10 mg of serrapeptase twice daily. Thirteen of these were better with electrophysiologic proof of recovery.(5)
It even crosses the blood brain barrier!
Important for Lyme Co-Infections.
Over the past 30 years studies and practitioners’ observations have shown benefits in a huge range of conditions including:
Arthritis, Inflammatory Migraines,
Blocked Arteries, Fibrocystic Breast Disease,
Breast engorgement Cancers.
Nothing surpasses the ability of serrapeptase to safely stop inappropriate chronic inflammation its tracks.
No matter the cause or the location, serrapeptase stops inflammation and dissolves fibrin biofilm tissue.(6)
Fibrin Activity and Scar Tissue Removal
As we said, one of the most significant features of serrapeptase is that it does not harm any living cells or tissues in the human body. We love it because it only dissolves non-living tissue including cysts and biofilms, scar tissue, mucous membrane, necrotic tissue, embolisms, and arterial plaque.(7) These same qualities make it equally effective in dissolving problem tissues in the human body.
Serrapeptase digests non-living tissue, blood clots, cysts, and arterial plaque and inflammation in all forms. However, probably the most important aspect of serrapeptase is its fibrinolytic activity (it dissolves fibrin)! For the treatment of Lyme disease, Dr. Lee Cowden now uses Serrapeptase to dissolve the fibrin layer surrounding the bacteria. This layer is associated with Lyme disease such as Borrelia, Babesia, Bartonella and Ehrlichia.
Studies conducted in Europe and Asia have shown that Serrapeptase is an effective fibrinolytic and it is this fibrin activity that is of particular interest to us. Improper build-up of fibrin becomes a significant risk factor for bacterial infectious diseases.
Serrapeptase also appears to remove scar tissue. One study showed 65% of carpal tunnel patients showed significant clinical improvement. No significant side effects were observed. The doctors concluded that serrapeptase therapy may prove to be a useful alternative conservative treatment.(8)
A double-blind study of a group with cystic breast disease were given serrapeptase. Over 85% of the patients receiving serrapeptase reporting moderate to marked improvement. This encourages the use of serrapeptase enzymes to help reduce the fibrin biofilms and cysts of Lyme disease and other infections. Serrapeptase induces fragmentation of fibrin aggregates thereby promoting the tissue repair process. (No adverse reactions were reported with the use of serrapeptase.)
Besides reducing inflammation and dissolving fibrin, one of serrapeptase's most profound benefits is reduction of pain! This is due to its ability to block the release of pain-inducing amines from inflamed tissues. It reduces inflammation in three ways:
1. It breaks down the insoluble protein by-products of blood coagulation known as fibrin;
2. It thins the fluids formed form inflammation and injury,
3. It facilitates their drainage which speeds the tissue repair process.
A study was conducted on the effect of serrapeptase on post-operative swelling and pain of the ankle. In the serrapeptase group, the swelling decreased by 50% on the third post-operative day, while in the control groups no reduction in swelling occurred. A decrease in pain correlated for the most part with the reduction in swelling. On the basis of these results, serrapeptase would appear to be an effective preparation for the post-operative reduction of swelling, in comparison with the classical conservative measures, for example, the application of ice.(9)
Of course, we have a special interest in how serrapeptase can help make our Monolaurin more effective in getting rid of Lyme disease. We know monolaurin kills Lyme when it can come into contact with it. It appears to be able to do this even with fibrin cyst and biofilm coatings. However, the biofilms can slow it down. The speed and efficiency of monolaurin can be increased with the help of these enzymes.
The fibrin layer covering Lyme co-infection microbes causes them to be hidden from the immune system. When using serrapeptase, once the fibrin is dissolved, the immune system can more easily identify fight the harmful microbes. With our Monolaurin, the job is even faster and more complete!
Re-Occurring Viral and Bacterial Infections
Many of the illnesses we deal with have the problem of a dormant bacteria or virus becoming re-activated after residing harmlessly for some time. An example is herpes. Herpes viruses may lie dormant for many years, only to revive at a later date – often after an acute illness or any event that injures the immune system.
When a virus contacts a human cell, the external coating connects to the cell. This connection permits the virus to contact the cell DNA and to reproduce in a rapid manner. Our proteolytic enzymes consume the exterior coating of a virus. This makes it more vulnerable to our Monolaurin to kill it.
These enzymes can also help an asthmatic or hay fever attack. They can help naturally decrease the amount of drainage and make it easier to cough up. A low dosage of 2-3 capsules daily can also make it more difficult for a new attack of asthma to get started.
Our enzymes also help our Chronic Inflammation Relief to block the release of pain producing amines from tissues that have inflammation. This elimination of pain benefits many conditions. Obviously, this really helps relieve joint pain in arthritic conditions and bursitis.
Sinus and migraine headaches can usually be helped by enzyme therapy. Adding the enzyme bromelain to our formula helped improve results because it lead to improved absorption of edema fluid, thus enabling greater penetration of immune system components.
Lung Disease and Enzyme Therapy
At a recent seminar, medical practitioners were shown how silkworm serrapeptase and other enzymes were able to break up slimy biofilms and uncover hidden Lyme disease bacteria. These special enzymes dissolve protective biofilms and enable medications, herbs, and the immune system to more effectively kill hidden germs.
When the biofilms are dissolved, our Monolaurin can get to the spirochetes to kill them. However, while dissolving the cysts is essential to solving Lyme disease, it can also release some toxins within them. This can cause a temporary increase in discomfort until the liver filters out the toxins. (Our Body Detox will help minimize discomfort by capturing and removing toxins.)
Special Capsules for Intestinal Absorption
Of course, to achieve an ideal therapeutic effect, it is essential that any enzyme preparation can be efficiently absorbed. When consumed in unprotected tablets or capsules, the enzyme is destroyed by acid in the stomach. However, our special capsules enable the enzyme to pass through the stomach unchanged, and be absorbed in the intestine. This releases the enzymes in the intestines (where they can be absorbed), not in the stomach (where they can be digested).
Several research groups have reported that serrapeptase is well absorbed orally when formulated with the ability to bypass the stomach. It is known that proteases and peptidases are only absorbed in the intestinal area. These enzymes are mobilized directly to the blood and are not easily detectible in urine. Other enzymes with structural similarities have been reported to be absorbed through the intestinal tract.
Serrapeptase is classified as a systemic enzyme (directly absorbed from intestine into the blood stream). Research confirms that serrapeptase is absorbed into the circulation in its active form.(1) Since in-vitro and in-vivo studies, including controlled studies, reveal that serrapeptase has a superior effect to that of other proteolytic enzymes, it makes serrapeptase is useful for a broad range of inflammatory and fibrin conditions.
Many of the experimental therapeutic daily dosages were about 30,000 – 40,000 iu daily. Why do we use more? The answer is simply because we have found it works better! In years of higher doses given by many, there have been no reports of any side effects from these doses except for a few people that had a pre-existing dysfunctional digestive tract.
Serrapeptase does not have a current upper limit for standard dosages. In fact, many physicians report that extra dosages are helpful in most cases. They usually tell their patients to take the medication at least 45 minutes prior to eating, or 1 hour after eating, in order to avoid any possible interference or unpleasant side effects (as we do also).
Some people report that they see more improvement in their conditions after the first few weeks. Skipping dosages can lead to fewer positive results.
The efficacy of serrapeptase was evaluated in a multicentre, double-blind, placebo-controlled study of 193 subjects. It was concluded that serrapeptase has anti-inflammatory, anti-edemic and anti-fibrin activity.(4)
Clearly, the potential applications for serrapeptase are many and varied. Whether the application is fibrinolytic, anti-inflammatory, analgesic, antibacterial, a mucolytic expectorant, as well as others, serrapeptase is the cutting edge in systemic enzyme therapy.
Combined with the other enzymes in our Bio-Fibrin and monolaurin, it makes a great team!
1. Esch PM, Gerngross H, Fabian A. Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase-- a prospective study (German). Fortschr Med. 1989 Feb 10;107(4):67-8, 71-2.
2. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, Guarini E, Vesperini G. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. Institute of Clinical Otorhinolaryngology, University of Naples, Italy. J Int Med Res. 1990; 18(5):379-88.
3. Mazzone A. et al Evaluation of serratia peptidase in acute or chronic inflammation of otolaryngogo;y pathology: A multi-cetre, double-blind, randomized trial versus placebo. J Int Med Res 1990, 379-88
4. Esch PM, et al Reduction of postoperative swelling objective measurement of the upper ankle joint in treatment with serrapeptase ------- A prospective study (German) Fortschr Med. 1989; 107(4)67-8, 71-2
5. Panaguriya A., et al A preliminary trial of serrapeptase in patients with carpal tunnel syndrome. J Assoc Physician India; 47(12):170-172
6. Sandhya KV, Devi SG, Mathew ST. Quantitation of serrapeptase in formulations by UV method in the microplate format. Curr Drug Deliv. 2008;5(4):303-305.
7. Mazzone A, Catalani M, Costanzo M, et al. Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: A multicentre, doubleblind, randomized trial versus placebo. J Int Med Res. 1990;18:379-388.
8. Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato K, Kakinuma A. Intestinal absorption of serrapeptase (TSP) in rats.
9. Tachibana M, Mizukoshi O, Harada Y, Kawamoto K, Nakai Y. A multi-centre, double-blind study of serrapeptase versus placebo in post-antrotomy buccal swelling. Pharmatherapeutica. 1984;3(8):526-30.
Bracale G, Selvetella L. Minerva Cardioangiol. Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase. (Article in Italian). 1996 Oct;44(10):515-24.
Kee WH, Tan SL, Lee V, Salmon YM. Singapore Med J. The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial. 1989 Feb;30(1):48-54.
Vicari E, La Vignera S, Battiato C, Arancio A. Minerva Urol Nefrol. Treatment with non-steroidal anti-inflammatory drugs in patients with amicrobial chronic prostato-vesiculitis: transrectal ultrasound and seminal findings. (Article in Italian). 2005 Mar;57(1):53-9.